Loring Wolcott & Coolidge Fiduciary Advisors’s Exact Sciences EXAS Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-45	Closed	-$2K	–	612
2022 Q2	$2K	Hold	45	–	–	﹤0.01%	609
2022 Q1	$3K	Sell	45 -458	-91%	-$33.5K	﹤0.01%	608
2021 Q4	$39K	Buy	503 +458	+1,018%	+$40.4K	﹤0.01%	485
2021 Q3	$4K	Hold	45	–	–	﹤0.01%	670
2021 Q2	$6K	Buy	+45	New	+$5.37K	﹤0.01%	715
2021 Q1	–	Sell	-45	Closed	-$6K	–	441
2020 Q4	$6K	Hold	45	–	–	﹤0.01%	668
2020 Q3	$5K	Hold	45	–	–	﹤0.01%	546
2020 Q2	$4K	Hold	45	–	–	﹤0.01%	544
2020 Q1	$3K	Hold	45	–	–	﹤0.01%	606
2019 Q4	$4K	Hold	45	–	–	﹤0.01%	616
2019 Q3	$4K	Sell	45 -84	-65%	-$9.57K	﹤0.01%	612
2019 Q2	$15K	Buy	129 +84	+187%	+$8.46K	﹤0.01%	532
2019 Q1	$4K	Buy	+45	New	+$3.83K	﹤0.01%	601

Other funds holding EXAS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's EXAS Position: Q3 2022 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Exact Sciences (EXAS) in Q3 2022, closing a stake of 45 shares — an estimated $2K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in EXAS in Q1 2019 and held it in 13 quarters. The position peaked at $39K in Q4 2021. 480 funds tracked by Wall St. Rank hold EXAS as of Q3 2022.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Exact Sciences position as of Q3 2022 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 45 Exact Sciences shares in Q3 2022, an estimated $2K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Exact Sciences in Q1 2019 and held it in 13 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Exact Sciences position peaked at $39K in Q4 2021.
480 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2022.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2022, filed 25 Oct 2022.